Loading patent…
AssigneesIucf-Hyu (Industry-University Cooperation Foundation Hanyang University), Industry-Academic Cooperation Foundation, Yonsei University
InventorsJin-Wu Nam, Bo-Hyun You, Sang Kil Lee, Jung Ho Yoon
Estimating the term…
The present invention pertains to a pharmaceutical composition for preventing or treating squamous cell carcinoma, the pharmaceutical composition containing a highly expressed lncRNAs in esophageal squamous cell carcinoma (HERES) expression inhibitor. More specifically, the present invention pertains to a pharmaceutical composition which uses a HERES expression inhibitor to reduce the expression of HERES and affect Wnt signaling pathways, and thereby prevent or treat squamous cell carcinoma. The present inventors discovered that the expression pattern of HERES is related to the onset of squamous cell carcinoma, and found that HERES can be a target for treating squamous cell carcinoma. Accordingly, the pharmaceutical composition according to the present invention was determined to have the effect of inhibiting the proliferation, metastasis, and the like of squamous cell carcinoma by containing the HERES expression inhibitor, and is thus expected to be advantageously used for preventing and treating or ameliorating squamous cell carcinoma.
A method for treating esophageal squamous cell carcinoma in an individual in need thereof, the method comprising administering, to the individual, an effective amount of a pharmaceutical composition comprising a Highly Expressed lncRNAs in Esophageal Squamous Cell Carcinoma (HERES) expression inhibitor as an active ingredient,
Dependencies are inferred from the claim text.